Bisphosphonate Toxicity

Etiology

Healthy bones maintain structural integrity through continuous remodeling. Two processes occur simultaneously: resorption of bone by osteoclasts and formation of new bone by osteoblasts. Maintaining a balanced interaction between these processes is essential for bone homeostasis. Several hormones contribute to the regulation of this balance. Growth factors, including insulin-like growth factor 1 and transforming growth factor β, are released during the resorption phase to stimulate subsequent bone formation. Hormones, such as parathyroid hormone and prostaglandin E, are thought to activate both resorption and formation concurrently.[6]

Structurally, bisphosphonates resemble calcium pyrophosphates. In healthy bone, calcium pyrophosphates bind to calcium, forming strong mineralized structures. Cancer-activated osteoclasts weaken the skeleton by resorbing bone tissue. Due to their structural similarity to calcium pyrophosphates, these osteoclasts also internalize bisphosphonates. Internalization disrupts osteoclast metabolism, ultimately inducing cell death. By suppressing osteoclast activity, bisphosphonates reduce bone turnover and limit skeletal degradation.

However, prolonged bisphosphonate use may lead to excessive inhibition of bone remodeling, resulting in skeletal fragility and atypical fractures, particularly in the femoral region. Evidence indicates that these atypical stress fractures arise from impaired cortical remodeling and delayed microdamage repair.[6] Bisphosphonate toxicity can occur with both therapeutic dosing and overdose. Risk is independent of renal or hepatic function. Adequate calcium and vitamin D intake before, during, and after therapy mitigates certain adverse effects, particularly hypocalcemia.[7]

Epidemiology

A recent meta-analysis of 47 studies involving breast cancer patients treated with intravenous bisphosphonates included 23 randomized controlled trials, encompassing a total of 20,607 patients. Influenza-like illness was the most frequently reported adverse effect, with no significant difference observed between sexes.[8] Additional side effects included fatigue, fever, dyspepsia, and anorexia. The overall incidence of osteonecrosis of the jaw (ONJ) among these patients was approximately 2%, markedly higher than in persons receiving oral bisphosphonates for osteoporosis, in whom the incidence ranges from 1 in 10,000 to 1 in 100,000 patient-years.[9] Atypical fractures are primarily associated with long-term bisphosphonate use, with a median duration of 7 years. The absolute risk of such fractures ranges from 3.2 to 50 cases per 100,000 patient-years.

History and Physical

The findings from the clinical history and examination of patients with bisphosphonate toxicity depend on the specific complications present. A thorough history, including medication exposure and a detailed review of systems, alongside a comprehensive physical examination, is essential to guide subsequent evaluation and management. 

Systemic Adverse Effects

Flu-like symptoms have been reported with intravenous bisphosphonate administration.[10] Affected patients may experience fever, fatigue, arthralgia, myalgia, nausea, and increased bone pain.[11] These symptoms typically develop within 24 to 72 hours following administration. The release of cytokines, including tumor necrosis factor α, interferon γ, and interleukin 6, is thought to precipitate the systemic inflammatory response.[12][13] Symptomatic treatment is generally sufficient, and the risk of recurrence decreases with subsequent infusions, declining from 30% after the 1st dose to less than 7% in later administrations.[14]

Upper Gastrointestinal Adverse Effects

Oral bisphosphonates are commonly associated with gastrointestinal adverse effects. Erosive esophagitis may occur, often related to suboptimal administration techniques. Patients should ingest the medication with a full glass of water and remain upright for 30 to 60 minutes afterward. The association between bisphosphonate use and nausea, dyspepsia, or abdominal pain is less well established. The occurrence of these symptoms should prompt evaluation for underlying gastrointestinal pathology prior to discontinuing therapy. Proton pump inhibitors may be used to mitigate these adverse effects.

Hypocalcemia

Several conditions increase the risk of hypocalcemia during bisphosphonate therapy. Current guidance emphasizes correction of vitamin D deficiency and preexisting hypocalcemia prior to the initiation of potent antiresorptive agents, with ongoing monitoring of calcium in high-risk patients, including those with hypoparathyroidism or osteoblastic metastases.[15] Vitamin D deficiency, hypoparathyroidism, and hypomagnesemia are all recognized predisposing factors. The risk is particularly elevated in patients with osteoblastic bone metastases. Clinical presentation is variable, ranging from nonspecific lethargy and weakness to severe tetany and seizures. Symptoms may develop within days of the 1st infusion but can also occur after months of repeated therapy.

Ocular Complications

Ocular adverse effects have been reported with 2nd- and 3rd-generation bisphosphonates, including pamidronate, zoledronate, and alendronate.[16] Even at recommended doses, pamidronate can induce scleritis, uveitis, and conjunctivitis. Pain and ocular redness have been observed following zoledronic acid infusion. Slit-lamp examination confirmed uveitis in several cases.

Osteonecrosis of the Jaw

ONJ is a condition characterized by destruction of the jawbone due to impaired blood supply, often associated with infection from oral flora.[17] The 1st documented case of ONJ related to bisphosphonate use was reported in 2003. The overall incidence of ONJ ranges from 1% to 10%, primarily affecting patients with cancer. Two main factors influence the likelihood of developing ONJ: the type and cumulative dose of bisphosphonates, and the presence of prior dental trauma. Higher-potency agents and prolonged exposure increase the risk. Intravenous bisphosphonates are associated with a 15-fold higher risk compared to oral formulations.[18] Literature indicates that the risk rises significantly after 2 to 3 years of therapy.[19]

The 2nd major factor is prior dental trauma, including dental extractions, oral surgery, or infections. Pain and exposed bone are the most common presenting features. Some patients report numbness, soft tissue swelling, or tooth mobility.[20] However, approximately 1/3 of cases are painless.[21] Rarely, patients present with fractures or fistula formation.

Radiographic imaging is generally unhelpful, as features are nonspecific. A suggestive history and characteristic clinical findings in the context of bisphosphonate use are usually sufficient for diagnosis. Recent position statements emphasize dental screening and optimization of oral health before initiating potent antiresorptives, particularly in oncologic settings. Stage-based management, ranging from conservative therapy to surgical intervention, is recommended based on severity.

Atypical Femoral Fractures

Several case reports and series describe a potential association between bisphosphonate therapy and subtrochanteric femoral fractures, although clinical trials have not conclusively demonstrated this link. These fractures typically occur spontaneously or following low-impact trauma. Subtrochanteric fractures are usually located in the proximal or midfemoral diaphysis and are observed in patients receiving long-term bisphosphonate therapy. Suspicion should be raised in patients reporting vague femoral pain or weakness.

More recent longitudinal and registry data indicate that atypical femoral fractures (AFFs) remain a rare but serious complication of prolonged bisphosphonate use. The risk increases with treatment duration and declines after discontinuation, supporting individualized reassessment of therapy beyond 3 to 5 years in lower-risk patients.[22] However, a notable proportion of AFFs occur in patients without prior antiresorptive exposure. Underlying metabolic or genetic disorders, such as adult hypophosphatasia, can predispose to AFF-type fractures. Clinicians should evaluate prodromal thigh or groin pain, obtain targeted imaging, and consider referral for metabolic bone assessment when appropriate.[23][24]

Evaluation

Laboratory studies provide valuable information in diagnosing complications of bisphosphonate therapy. Low hemoglobin levels may indicate erosive esophagitis. Measurement of calcium and vitamin D levels assists in identifying hypocalcemia. Rising creatinine is a key indicator of nephrotoxicity.

Imaging studies aid in the evaluation of skeletal complications. Plain radiographs can reveal AFFs, typically transverse, sometimes oblique, with a characteristic cortical “beak.” Technetium-99m bone scans demonstrate increased uptake at affected sites. Magnetic resonance imaging is useful when radiographs are unremarkable despite high clinical suspicion. Fracture lines appear as low-signal regions on T1, T2, and short τ inversion recovery (STIR) sequences, while surrounding marrow shows low signal on T1 and high signal on T2 and STIR images.

Treatment / Management

Management of Acute-Phase Reactions

These systemic reactions are typically self-limiting. The primary management strategy is supportive, using acetaminophen with or without nonsteroidal anti-inflammatory drugs. Acute-phase reactions generally resolve within 48 hours. Premedication with acetaminophen is recommended for subsequent doses. Other potential causes of fever, such as infection, should be excluded.

Addressing Upper Gastrointestinal Adverse Effects

Proper administration of bisphosphonates can prevent many gastrointestinal complications. Bisphosphonates should be avoided in patients with chronic esophageal disorders, including Barrett esophagus.

Mitigation of Hypocalcemia

Management involves identifying predisposing factors such as prior head and neck radiotherapy, thyroidectomy, and hypomagnesemia. Existing hypocalcemia should be corrected and monitored throughout therapy. Correction of preexisting hypocalcemia or vitamin D deficiency is strongly recommended prior to initiating bisphosphonate therapy.

Management of Ocular Complications

Ocular adverse effects are rare and usually not vision-threatening. Referral to an ophthalmologist is advised for appropriate evaluation and management of these complications.

Approach to Osteonecrosis of the Jaw

Prevention and early identification of high-risk patients are central strategies in ONJ management.[25] Dental evaluation and any necessary treatment are recommended prior to initiating bisphosphonate therapy in these patients. Patient education regarding the risk of ONJ and the benefits of ongoing prophylactic dental care is essential.[26]

A drug holiday has been proposed as a prophylactic measure to reduce the risk of MRONJ. This intervention involves a temporary cessation of bisphosphonate therapy before planned dentoalveolar procedures.[27] Cohort studies and meta-analyses indicate that in patients at low-to-moderate fracture risk who have completed 3 to 5 years of therapy, a temporary drug holiday may reduce rare complications such as AFF or MRONJ. However, high-risk patients may require continued therapy or transition to alternative agents. 

Management is challenging once MRONJ develops. Treatment depends on disease severity and ranges from conservative care to surgical debridement and resection of affected tissues. Conservative management consists of regular dental visits, chlorhexidine mouthwash, and antibiotics for infections. Surgical intervention is reserved for cases that are refractory to conservative care or involve persistent bone exposure.[28] Adjunctive modalities, including oxygen therapy and the application of mesenchymal cells for bone regeneration, have also been trialed.(B2)

Interventions for Subtrochanteric Femoral Fractures

Bisphosphonate therapy should be discontinued once the fracture is confirmed. Calcium and vitamin D supplementation should be considered. Orthopedic consultation is recommended to guide fracture management.

Differential Diagnosis

Other conditions can present with radiographic features similar to ONJ, including radiation-induced osteonecrosis and infections.[29] Differential diagnoses for AFFs include trauma, osteoarthritis, pathologic fractures from metastases, and inflammatory arthritis.

Prognosis

The prognosis depends on the specific complications present. Flu-like symptoms are generally benign and self-limiting. In contrast, erosive esophagitis, ONJ, and nephrotoxicity represent serious complications associated with substantial morbidity and potential mortality.

Complications

Nephrotoxicity

Particular caution is required when administering bisphosphonates to patients with preexisting renal impairment.[30] Recent observational analyses indicate an increased risk of acute kidney injury in older adults treated with intravenous bisphosphonates, particularly in those with underlying chronic kidney disease. Baseline renal function assessment and close monitoring are recommended.[31]

Renal toxicity risk is higher in patients receiving cancer chemotherapy. Bisphosphonates primarily induce kidney injury through acute tubular necrosis. Biochemical evidence includes a gradual rise in creatinine levels over several months. Discontinuation of therapy usually results in normalization of renal function within months.[32]

The incidence of MRONJ is higher in patients with cancer receiving high-dose intravenous bisphosphonates or concomitant antiangiogenic therapies. Thus, preventive dental management differs. In individuals with chronic kidney disease, careful risk–benefit assessment is critical due to altered pharmacokinetics and increased renal susceptibility.

Among bisphosphonates, zoledronic acid carries the highest risk of renal failure. The risk increases with higher doses and longer infusion times.[33] Zoledronic acid induces renal tubular damage by altering key metabolic pathways. Microscopically, the injury resembles acute tubular necrosis. Recovery from zoledronic acid–induced renal injury is possible but typically slow.[34]

Nephrotoxicity from pamidronate typically presents as nephrotic syndrome. Microscopically, findings vary and may include focal segmental glomerulosclerosis, acute tubular injury, or minimal change disease without glomerular involvement.[35] These changes are generally irreversible and are most often observed in patients receiving the maximum recommended dose of 90 mg.[36]

Pamidronate-related nephrotic syndrome, particularly when accompanied by renal failure, carries a poor prognosis. Approximately 1/5 of affected patients recover renal function, and about 50% eventually require renal replacement therapy. Therefore, early detection and discontinuation of pamidronate are critical in management.

Prevention and early identification of renal failure are central strategies in managing bisphosphonate-induced nephrotoxicity. Preventive measures include preinfusion serum creatinine assessment, adequate hydration, avoidance of concomitant nephrotoxic medications, and dose adjustments in patients with mild renal insufficiency.[37] Zoledronic acid and pamidronate are generally not recommended when creatinine clearance is below 30 mL/min or serum creatinine doubles from baseline.

The initial step upon detection of nephrotoxicity is to discontinue the bisphosphonate. Management is largely supportive, as no specific therapy has demonstrated efficacy. Reintroduction of the medication may be considered if potential benefits outweigh risks, with decisions made on a case-by-case basis following detailed discussion with the patient.

Atrial Fibrillation

An association between bisphosphonate therapy and atrial fibrillation has been proposed. Large clinical trials, including the Fracture Intervention Trial and the HORIZON Pivotal Fracture Trial, reported an increased incidence of atrial fibrillation (1.3% in the zoledronic acid group versus 0.5% in the placebo group). However, subsequent observational studies found no consistent association.

Retrospective analyses to date provide inconclusive evidence, neither confirming nor completely excluding a link. Bisphosphonates are typically administered to older patients with preexisting comorbidities, including atrial fibrillation, which may confound the association. Further prospective studies are needed to clarify the potential relationship.[38]